Viridian Therapeutics Inc (VRDN) Stock deserves your attention
Ladenburg Thalmann raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock from “a Buy” to “a Neutral”. The rating was released on May 09, 2024, according to finviz. We previously noted in another research note published on May 09, 2024 by B. Riley Securities that downgraded the stock from a Buy to a […]
Credit Suisse Assigned “an Outperform” Rating to Viridian Therapeutics Inc (NASDAQ:VRDN) Stock
Credit Suisse raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 14, 2023, according to finviz. The research report from RBC Capital Mkts has initiated the stock to Outperform, with a price target set at $44. The stock was initiated by Wells Fargo, who […]
Are there any attempts to gain ground? Viridian Therapeutics Inc (VRDN) Stock
Credit Suisse raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 14, 2023, according to finviz. The research report from RBC Capital Mkts has initiated the stock to Outperform, with a price target set at $44. The stock was initiated by Wells Fargo, who […]
The future of Viridian Therapeutics Inc (VRDN) Stock is still in tatters?
Credit Suisse raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 14, 2023, according to finviz. The research report from RBC Capital Mkts has initiated the stock to Outperform, with a price target set at $44. The stock was initiated by Wells Fargo, who […]
It’s not the right time to quit: Viridian Therapeutics Inc (VRDN) Stock
Credit Suisse raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 14, 2023, according to finviz. The research report from RBC Capital Mkts has initiated the stock to Outperform, with a price target set at $44. The stock was initiated by Wells Fargo, who […]
Facts about Viridian Therapeutics Inc (VRDN) Stock that you might not know
Credit Suisse raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 14, 2023, according to finviz. The research report from RBC Capital Mkts has initiated the stock to Outperform, with a price target set at $44. The stock was initiated by Wells Fargo, who […]
Viridian Therapeutics Inc (NASDAQ:VRDN) stock Posted Operating Margin of -81035.35 percent in Last Year: Is Admissible?
Credit Suisse raised the price target for the Viridian Therapeutics Inc (NASDAQ:VRDN) stock to “an Outperform”. The rating was released on June 14, 2023, according to finviz. The research report from RBC Capital Mkts has initiated the stock to Outperform, with a price target set at $44. The stock was initiated by Wells Fargo, who […]
